# Efficacy and Safety Study of Eprotirome in HeFH Patients Who Are on Optimal Standard of Care

> **NCT01410383** · PHASE3 · TERMINATED · sponsor: **Karo Bio AB** · enrollment: 236 (actual)

## Conditions studied

- Heterozygous Familial Hypercholesterolaemia

## Interventions

- **DRUG:** Placebo
- **DRUG:** Eprotirome
- **DRUG:** Eprotirome

## Key facts

- **NCT ID:** NCT01410383
- **Lead sponsor:** Karo Bio AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-10
- **Primary completion:** 2013-10
- **Final completion:** 2014-10
- **Target enrollment:** 236 (ACTUAL)
- **Last updated:** 2012-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01410383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01410383, "Efficacy and Safety Study of Eprotirome in HeFH Patients Who Are on Optimal Standard of Care". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01410383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*